.png)
.png)
Latest news from BIA
BIA announces major initiative with AstraZeneca and new state of the art lifescience innovation campus in Wuxi China
The BioIndustry Association (BIA) has signed a memorandum of understanding with the Wuxi International Life-science Innovation Campus (I-Campus) and AstraZeneca in China. The state-of-the-art campus will enable UK SMES companies to easily explore, partner and engage with China’s rapidly expanding healthcare innovation market. The I-campus will also serve as AstraZeneca’s new China headquarters.
BIA welcomes Chancellor’s commitment to raising R&D investment in Spending Round
Steve Bates OBE, CEO of the BIA said: “We are pleased to see the new administration’s confirmation that the UK is still committed to raising R&D investment and that a new plan to give long-term certainty to the scientific community will be delivered in the Autumn.
The NHS’ rapid adoption of cell and gene therapies will boost availability of innovative therapies for patients says BIA
The UK BioIndustry Association (BIA) has welcomed today’s announcement that the NHS will be providing cell and gene therapies to treat patients with inherited retinal dystrophies.
BIA reaction to Chancellor's announcement on no deal funding
A BIA spokesperson said: "The announced £434 million for medicines and medical products is significant investment, and recognition of the work of DHSC in this area, however we now need the detail of how the money will be spent.
Repositive appoints Slaven Stekovic as Head of Strategic Growth and leading commercial advisers to drive the company’s scale-up and global growth ambitions
Repositive – the Cambridge-based startup that connects researchers with the right preclinical cancer models for their research – today announced the appointment of Slaven Stekovic as Head of Strategic Growth, along with leading commercial experts (Mariana Vaschetto and Francesca Crawford) to its advisory board, to drive the company’s scale-up and global growth ambitions within the pharma and biotech market.
Coulter Partners secures Non-Executive Director for Nanoform
Coulter Partners was very pleased to partner once more with innovative medicine enabling nanotechnology company, Nanoform to secure the appointment of Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
IQVIA joins landmark UK health data digital initiative
IQVIA will deliver technology and capabilities to support DATA-CAN, the new national Health Data Research Hub for Cancer, to improve outcomes for NHS cancer patients.
Mogrify appoints Dr. Jane Osbourn, OBE as Chair
Cambridge, UK, 9th September 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr. Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr. Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.
CEO Update | Monday 16 September 2019
Last week hidden beneath the Government's announcement that students will be able to stay in the UK for two years, there were developments on the UK life science industrial strategy, which the BIA has partnered with government on for the last three years.
Smelling the disease - Nosing our way towards earlier diagnosis and new biomarkers
Could the sense of smell drive future biological detection methods? In university and drug company labs which develop assays for diseases and for measuring drug effects, you will find a range of readers for measuring changes in biological systems.
Guest blog | UK Synthetic Biology Startup Survey - 2019
Stephen Chambers, founder of the Subsero and Entrepreneur in Residence at the Royal Society, breaks down the trends in the UK’s synthetic biology start-up community.
CEO Update | Monday 09 September 2019
The BIA has signed a major deal in China, enabling UK life Science companies to gain an effective first landing place in this exciting and innovative market. Chair of the BIA, Dr Jane Osbourn OBE attended the opening ceremony of the Wuxi International Life-science Innovation Campus (I-Campus), where a memorandum of understanding was signed between the I-campus, the BIA and AstraZeneca. This is a key initiative for the BIA to make it easier for UK life sciences SMEs to do business in China.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
